Screener
Arbutus Biopharma Corporation ABUS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Arbutus Biopharma Corporation in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Arbutus Biopharma Corporation’s 10-Q, filed August 12, 2026. Open the filing →
- Filed
- Aug 12, 2026, 7:31 AM EDT
- Fiscal quarter
- Q3 FY2026
- Calendar quarter
- Q3 2026
- Accession
- 0001447028-26-000045
FAQ
- What is Arbutus Biopharma Corporation's total liabilities?
- Arbutus Biopharma Corporation (ABUS) reported total liabilities of $15.29M in Q2 2026.
- How has Arbutus Biopharma Corporation's total liabilities changed year-over-year?
- Arbutus Biopharma Corporation's total liabilities decreased by 24.6% year-over-year, from $20.29M to $15.29M.
- What is the long-term trend for Arbutus Biopharma Corporation's total liabilities?
- Over 5 years (2020 to 2025), Arbutus Biopharma Corporation's total liabilities has grown at a -12.5% compound annual growth rate (CAGR), from $35.11M to $18.04M.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Arbutus Biopharma Corporation's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude